Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Rev. Assoc. Med. Bras. (1992, Impr.) ; 67(supl.1): 18-21, 2021.
Article Dans Anglais | LILACS | ID: biblio-1287838

Résumé

SUMMARY COVID-19 infection is more severe in patients with type 2 diabetes mellitus (DM2). The severity of this viral infection is associated with an intense inflammatory activity. DM2 is a disease that also determines a greater degree of systemic inflammation. This is due to hyperglycemia, the higher prevalence of sleep disorders and also the low levels of melatonin, a substance with anti-inflammatory actions, in these patients. In this article, we suggest that exogenous melatonin may have an important anti-inflammatory role in preventing severe forms of COVID -19 in patients with DM2.


Sujets)
Diabète de type 2/complications , Diabète de type 2/traitement médicamenteux , COVID-19 , Hyperglycémie , SARS-CoV-2 , Mélatonine/usage thérapeutique
SÉLECTION CITATIONS
Détails de la recherche